SCHEMBL6512957

SCHEMBL6512957

Cc1c2c(=O)[nH]c3ccc(F)cc3c2nn1C1CCCCO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.43
ALDH1A1 P00352 4/20 0.41
HSD17B10 Q99714 3/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 2/20 0.37
GLA P06280 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
CDC25A P30304 1/20 0.35
CDC25C P30307 1/20 0.35
CSF1R P07333 1/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
TYMS P04818 1/20 0.34
CHEK1 O14757 1/20 0.34
ESR1 P03372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6046806 0.88 IDH1 (0.36) KDM4EALDH1A1CYP4F2CYP4A11CSF1R
SCHEMBL6508753 0.88 CHEK1 (0.47) KDM4EALDH1A1HSD17B10LMNANPSR1
SCHEMBL6511000 0.84 PTGS2 (0.46) ALDH1A1LMNANPSR1CSF1RPOLB
SCHEMBL6508991 0.84 PARP1 (0.44) KDM4EALDH1A1HSD17B10GLANPSR1
SCHEMBL6510843 0.82 CHEK1 (0.47) ALDH1A1LMNACDC25ACDC25CCSF1R
SCHEMBL6529957 0.81 PARP1 (0.37) KDM4EALDH1A1IDH1
SCHEMBL6510968 0.78 DRD1 (0.33)
SCHEMBL6522020 0.75 CHEK1 (0.43) KDM4EALDH1A1HSD17B10LMNACSF1R
SCHEMBL6523130 0.74 ATR (0.44)
SCHEMBL6508818 0.72 CHEK1 (0.39) KDM4EALDH1A1HSD17B10LMNACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 KDM4E 1251/4885ALDH1A1 4635/4885HSD17B10 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.